NCT04788355 - Prevention of Complications (SARS-CoV-2): Clinical Study | Biotech Hunter

Enrollment

176

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

November 15, 2020

Study Completion Date

December 23, 2020

Conditions

Complication

Interventions

DRUG

Control group (standard hospital treatment)

Medications defined by the hospital involved in the study

DRUG

Group Hydroxychloroquine

Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days. In addition, patients in this group will receive standard medication for COVID-19 which is part of the hospital protocol involved in the study.

DRUG

Group Hydroxychloroquine and apixaban

Patients in this group will receive hydroxychloroquine orally 200 mg every 12 hours for 7 days + apixaban orally 2.5 mg every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.

DRUG

Group Apixaban

Patients in this group will receive apixaban 2.5 mg orally every 12 hours, also for 14 days (prophylactic dose). In addition, patients in this group will receive standard medication, which is the protocol of the hospital involved in the study.

Trial Locations (1)

37550000

Univás, Pouso Alegre